title: Novel therapies in peripheral T-cell lymphomas.
abstract: Peripheral T-cell lymphomas (PTCLs) are a rare and heterogeneous group of disorders associated with a very poor prognosis. Historically, treatment protocols have been largely based on regimens used to treat aggressive B-cell lymphomas; unfortunately, the efficacy of these regimens has been suboptimal, with most patients experiencing relapse after initial therapy. An improved understanding of the molecular biology, pathogenesis, and progression of these disorders has led to the development of a variety of novel targeted agents that may improve outcomes in patients with PTCLs. The purpose of this review is to focus on these novel agents and the various treatment approaches that are currently being evaluated in PTCLs.
authors.affiliation: Department of Medical Oncology, British ColumbiaCancer Agency, 600 West 10th Avenue, Vancouver,British Columbia, Canada.
authors.forename: Hilary M
authors.initials: HM
authors.lastname: O'Leary
authors.forename: Kerry J
authors.initials: KJ
authors.lastname: Savage
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005492:Folic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use; D006801:Humans; D000922:Immunotoxins / Q000276:immunology / Q000627:therapeutic use; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy*; D009705:Nucleosides / Q000737:chemistry / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors; D000922:Immunotoxins; D009705:Nucleosides; D005492:Folic Acid